Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOTABREAST: 68Ga-DOTATOC PET in Metastatic Breast Cancer
NCT06611891Phase 3Recruiting
- Sponsor
- CHU Grenoble Alpes
- Start
- Jan 2025
- Primary completion
- Oct 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gallium Ga 68-edotreotide in breast cancer, sponsored by CHU Grenoble Alpes. Primary endpoint: Presence of lesions expressing SST2 receptors in 68Ga-DOTATOC. Started Jan 2025; status: recruiting.
02
Drugs
gallium Ga 68-edotreotide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06611891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06611891.